Inoperable ESCC: Should Radiotherapy Be Deferred After Starting Chemoimmunotherapy?: eClinicalMedicine | September 2026

What Did the Study Find?

This large Chinese real-world study evaluated 1,242 patients with inoperable esophageal squamous cell carcinoma (ESCC) receiving first-line chemoimmunotherapy (CIT), comparing upfront radiotherapy (RT) with a strategy of deferred RT.

• Deferred RT was associated with longer overall survival: 44.1 vs 33.4 months (adjusted HR 0.70).
• Median PFS was also longer: 21.1 vs 16.0 months (adjusted HR 0.76).
• At 3 years, OS was 57.5% with deferred RT vs 41.9% with upfront RT.
• Three-year PFS was 33.8% vs 22.4%, respectively.
• The investigators used target-trial emulation, inverse-probability weighting and clone-censor-weight methods to reduce selection and immortal-time biases.
• Findings remained consistent across sensitivity and subgroup analyses.
• Severe treatment-related esophageal fistula occurred in 4.8% with deferred RT vs 9.0% with upfront RT.
• RT exposure also differed between strategies: median dose was 60 Gy upfront vs 50.4 Gy in the deferred group.

Why Does It Matter?

As immunotherapy moves into first-line ESCC treatment, the question is no longer simply whether to combine RT with systemic therapy, but when RT should be delivered. These data raise the possibility that initial systemic disease control with CIT followed by appropriately timed RT may provide a better therapeutic balance than immediate combined treatment.

GastroAGI Takeaway

In inoperable ESCC receiving chemoimmunotherapy, “radiotherapy first” may not necessarily be the optimal sequence. Deferred RT was associated with approximately 11 months longer median OS, better PFS and numerically fewer severe esophageal fistulas.